• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Applied DNA Sciences, Inc. - Common Stock (NQ:APDN)

5.620 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Applied DNA Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy
October 06, 2025
From Applied DNA Sciences, Inc.
Via Business Wire
News headline image
Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
September 29, 2025
From Applied DNA Sciences, Inc.
Via Business Wire
News headline image
Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
September 23, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
February 13, 2025
Via ACCESS Newswire
News headline image
Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
February 12, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
August 14, 2025
Via ACCESS Newswire
News headline image
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
July 24, 2025
Via ACCESS Newswire
News headline image
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
July 07, 2025
Via ACCESS Newswire
News headline image
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
June 30, 2025
Via ACCESS Newswire
News headline image
Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
January 10, 2025
Via ACCESSWIRE
News headline image
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
June 17, 2025
Via ACCESS Newswire
News headline image
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
June 16, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reschedules Intra-Quarter Webcast and Investor Update Call to June 17
May 29, 2025
Via ACCESS Newswire
News headline image
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
May 29, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reports Second Quarter Fiscal 2025 Financial Results
May 15, 2025
Via ACCESS Newswire
News headline image
Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3
May 14, 2025
Via ACCESS Newswire
News headline image
Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA
April 21, 2025
Via ACCESS Newswire
News headline image
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 08, 2025
Via ACCESS Newswire
News headline image
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
April 01, 2025
Via ACCESS Newswire
News headline image
Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test
March 26, 2025
Via ACCESS Newswire
News headline image
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
March 12, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
February 11, 2025
Via ACCESS Newswire
News headline image
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
January 08, 2025
Via ACCESSWIRE
News headline image
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
December 18, 2024
Via ACCESSWIRE
News headline image
Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
December 17, 2024
Via ACCESSWIRE
News headline image
Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
December 16, 2024
Via ACCESSWIRE
News headline image
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
October 30, 2024
Via ACCESSWIRE
News headline image
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
October 15, 2024
Via ACCESSWIRE
News headline image
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 18, 2024
Via ACCESSWIRE
News headline image
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
September 17, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap